Lipid‑based nanoparticles for the therapeutic delivery of non‑coding RNAs in breast cancer (Review)

Silva‑Cázares,Macrina B.; Saavedra‑Leos,María Z.; Jordan‑Alejandre,Euclides; Nuñez‑Olvera,Stephanie I.; Cómpean‑Martínez,Isaac; López‑Camarillo,César

doi:10.3892/or.2020.7791

Lipid‑based nanoparticles for the therapeutic delivery of non‑coding RNAs in breast cancer (Review)

Authors:
- Macrina B. Silva‑Cázares
- María Z. Saavedra‑Leos
- Euclides Jordan‑Alejandre
- Stephanie I. Nuñez‑Olvera
- Isaac Cómpean‑Martínez
- César López‑Camarillo
View Affiliations

Affiliations: Institutional Doctorate in Engineering and Matherials Science, Autonomous University of San Luis Potosí, San Luis Potosí 78760, México, Oncogenomics Laboratory, Autonomous University of México City, México City 03100, México
Published online on: October 5, 2020 https://doi.org/10.3892/or.2020.7791
Pages: 2353-2363

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Breast cancer is the most common type of cancer with the highest morbidity and mortality rates in women worldwide. Recent efforts to improve the current antitumor therapies have led to the development of novel treatment approaches based on the delivery of therapeutic non‑coding RNAs (ncRNAs) using nanotechnology. Treatment methods using lipid‑based nanoparticles (LBNPs) have greatly improved the delivery efficiency of ncRNAs into tumor cells and tissues. This type of delivery approach has provided significant advantages, such as reduced therapeutic doses, lower cytotoxicity to normal cells and the ability to reverse resistance to chemotherapy. LBNPs have demonstrated the ability to deliver therapeutic ncRNAs, more specifically microRNAs (miRNAs) and small interfering RNAs (siRNAs); this has been reported modulate the expression levels of oncogenes and tumor suppressor genes involved in several biological processes, including cell growth and proliferation, cell death, invasion and metastasis, thus impairing the malignant behavior of tumors. Therefore, ncRNA‑based therapies combined with the LBNP delivery strategy, namely nanomiRNAs, may represent a promising antitumor strategy guaranteeing superior biocompatibility, higher biodegradability, lower immunogenicity and decreased toxicity to normal cells compared with other therapeutic approaches. The present review summarized the current knowledge of the application of LBNPs for delivering miRNAs and siRNAs in breast cancer cells and mouse models, in addition to discussing their promising antitumor effects.

View Figures

View References

1	Cavallo F, Giovanni C, Nanni P, Forni G and Lollini PL: 2011: The immune hallmarks of cancer. Cancer Immunol Immunother. 60:319–326. 2011. View Article : Google Scholar : PubMed/NCBI
2	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
3	Cronin KA, Lake AJ, Scott S, Sherman RL, Noone AM, Howlader N, Henley SJ, Anderson RN, Firth AU, Ma J, et al: Annual report to the nation on the status of cancer, part I: National cancer statistics. Cancer. 124:2785–2800. 2018. View Article : Google Scholar : PubMed/NCBI
4	Breast Cancer Treatment\|Treatment Options for Breast Cancer.
5	Miller KD, Nogueira L, Mariotto AB, Rowland JH, Yabroff KR, Alfano CM, Jemal A, Kramer JL and Siegel RL: Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin. 69:363–385. 2019. View Article : Google Scholar : PubMed/NCBI
6	Hanahan D and Weinberg RA: The hallmarks of cancer. Cell. 100:57–70. 2000. View Article : Google Scholar : PubMed/NCBI
7	Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
8	Yingchoncharoen P, Kalinowski DS and Des Richardson R: Lipid-based drug delivery systems in cancer therapy: What is available and what is yet to come. Pharmacol Rev. 68:701–787. 2016. View Article : Google Scholar : PubMed/NCBI
9	Mudshinge SR, Deore AB, Patil S and Bhalgat CM: Nanoparticles: Emerging carriers for drug delivery. Saudi Pharm J. 19:129–141. 2011. View Article : Google Scholar : PubMed/NCBI
10	Del Pozo-Rodríguez A, Solinís MÁ and Rodríguez-Gascón A: Applications of lipid nanoparticles in gene therapy. Eur J Pharm Biopharm. 109:184–193. 2016. View Article : Google Scholar : PubMed/NCBI
11	Hashemi M and Kalalinia F: Application of encapsulation technology in stem cell therapy. Life Sci. 143:139–146. 2015. View Article : Google Scholar : PubMed/NCBI
12	Aagaard L and Rossi JJ: RNAi therapeutics: Principles, prospects and challenges. Adv Drug Deliv Rev. 59:75–86. 2007. View Article : Google Scholar : PubMed/NCBI
13	Chen G, Wang Y, Xie R and Gong S: Tumor-targeted pH/redox dual-sensitive unimolecular nanoparticles for efficient siRNA delivery. J Control Release. 259:105–114. 2017. View Article : Google Scholar : PubMed/NCBI
14	Deng X, Cao M, Zhang J, Hu K, Yin Z, Zhou Z, Xiao X, Yang Y, Sheng W, Wu Y and Zeng Y: Hyaluronic acid-chitosan nanoparticles for co-delivery of MiR-34a and doxorubicin in therapy against triple negative breast cancer. Biomaterials. 35:4333–4344. 2014. View Article : Google Scholar : PubMed/NCBI
15	Hogrefe RI, Lebedev AV, Zon G, Pirollo KF, Rait A, Zhou Q, Yu W and Chang EH: Chemically modified short interfering hybrids (siHYBRIDS): Nanoimmunoliposome delivery in vitro and in vivo for RNAi of HER-2. Nucleosides Nucleotides Nucleic Acids. 25:889–907. 2006. View Article : Google Scholar : PubMed/NCBI
16	Shu D, Li H, Shu Y, Xiong G, Carson WE III, Haque F, Xu R and Guo P: Systemic delivery of Anti-miRNA for suppression of triple negative breast cancer utilizing RNA nanotechnology. ACS Nano. 9:9731–9740. 2015. View Article : Google Scholar : PubMed/NCBI
17	Urban-Klein B, Werth S, Abuharbeid S, Czubayko F and Aigner A: RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo. Gene Ther. 12:461–466. 2005. View Article : Google Scholar : PubMed/NCBI
18	Yhee JY, Song S, Lee SJ, Park SG, Kim KS, Kim MG, Son S, Koo H, Kwon IC, Jeong JH, et al: Cancer-targeted MDR-1 siRNA delivery using self-cross-linked glycol chitosan nanoparticles to overcome drug resistance. J Control Release. 198:1–9. 2015. View Article : Google Scholar : PubMed/NCBI
19	Guo P, You JO, Yang J, Di J, Moses MA and Auguste DT: Inhibiting metastatic breast cancer cell migration via the synergy of targeted, pH-triggered siRNA delivery and chemokine axis blockade. Mol Pharm. 11:755–765. 2014. View Article : Google Scholar : PubMed/NCBI
20	Reichmuth AM, Oberli MA, Jaklenec A, Langer R and Blankschtein D: mRNA vaccine delivery using lipid nanoparticles. Ther Deliv. 7:319–334. 2016. View Article : Google Scholar : PubMed/NCBI
21	de la Harpe K, Kondiah P, Choonara Y, Marimuthu T, du Toit L and Pillay V: The hemocompatibility of nanoparticles: A review of cell-nanoparticle interactions and hemostasis. Cells. 8:12092019. View Article : Google Scholar
22	Buzea C, Pacheco II and Robbie K: Nanomaterials and nanoparticles: Sources and toxicity. Biointerphases. 2:MR17–MR71. 2007. View Article : Google Scholar : PubMed/NCBI
23	Huang Y, Gao X and Chen J: Leukocyte-derived biomimetic nanoparticulate drug delivery systems for cancer therapy. Acta Pharm Sin B. 8:4–13. 2018. View Article : Google Scholar : PubMed/NCBI
24	Huynh A, Madu CO and Lu Y: siRNA: A promising new tool for future breast cancer therapy. Oncomedicine. 3:74–81. 2018. View Article : Google Scholar
25	Singh A, Trivedi P and Jain NK: Advances in siRNA delivery in cancer therapy. Artif Cells Nanomed Biotechnol. 46:274–283. 2018. View Article : Google Scholar : PubMed/NCBI
26	Hayward SL, Francis DM, Kholmatov P and Kidambi S: Targeted delivery of MicroRNA125a-5p by engineered lipid nanoparticles for the treatment of HER2 positive metastatic breast cancer. J Biomed Nanotechnol. 12:554–568. 2016. View Article : Google Scholar : PubMed/NCBI
27	Liu J, Meng T, Ming Y, Wen L, Cheng B, Liu N, Huang X, Hong Y, Yuan H and Hu F: MicroRNA-200c delivered by solid lipid nanoparticles enhances the effect of paclitaxel on breast cancer stem cell. Int J Nanomedicine. 11:6713–6725. 2016. View Article : Google Scholar : PubMed/NCBI
28	Wang X, Yu B, Wu Y, Lee RJ and Lee LJ: Efficient down-regulation of CDK4 by novel lipid nanoparticle-mediated siRNA delivery. Anticancer Res. 31:1619–1626. 2011.PubMed/NCBI
29	Tang J, Howard CB, Mahler SM, Thurecht KJ, Huang L and Xu ZP: Enhanced delivery of siRNA to triple negative breast cancer cells in vitro and in vivo through functionalizing lipid-coated calcium phosphate nanoparticles with dual target ligands. Nanoscale. 10:4258–4266. 2018. View Article : Google Scholar : PubMed/NCBI
30	Yu YH, Kim E, Park DE, Shim G, Lee S, Kim YB, Kim CW and Oh YK: Cationic solid lipid nanoparticles for co-delivery of paclitaxel and siRNA. Eur J Pharm Biopharm. 80:268–273. 2012. View Article : Google Scholar : PubMed/NCBI
31	Zheng ZM, Tang S and Tao M: Development of resistance to RNAi in mammalian cells. Ann NY Acad Sci. 1058:105–118. 2005. View Article : Google Scholar : PubMed/NCBI
32	Guo H, Ingolia NT, Weissman JS and Bartel DP: Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature. 466:835–840. 2010. View Article : Google Scholar : PubMed/NCBI
33	Yang W, Lee DY and Ben-David Y: The roles of microRNAs in tumorigenesis and angiogenesis. Int J Physiol Pathophysiol Pharmacol. 3:140–155. 2011.PubMed/NCBI
34	Kwon T, Chandimali N, Huynh DL, Zhang JJ, Kim N, Bak Y, Yoon DY, Yu DY, Lee JC, Gera M, et al: BRM270 inhibits cancer stem cell maintenance via microRNA regulation in chemoresistant A549 lung adenocarcinoma cells. Cell Death Dis. 9:2442018. View Article : Google Scholar : PubMed/NCBI
35	Zhao M, Ang L, Huang J and Wang J: MicroRNAs regulate the epithelial-mesenchymal transition and influence breast cancer invasion and metastasis. Tumour Biol. 39:1010428317691682. 2017. View Article : Google Scholar
36	Barbarotto E and Calin GA: MicroRNAs and drug resistance. Drug Resistance Cancer Cells. 102:257–270
37	Kim J, Yao F, Xiao Z, Sun Y and Ma L: MicroRNAs and metastasis: Small RNAs play big roles. Cancer Metastasis Rev. 37:5–15. 2018. View Article : Google Scholar : PubMed/NCBI
38	McGuire A, Brown JA and Kerin MJ: Metastatic breast cancer: The potential of miRNA for diagnosis and treatment monitoring. Cancer Metastasis Rev. 34:145–155. 2015. View Article : Google Scholar : PubMed/NCBI
39	Volinia S, Galasso M, Sana ME, Wise TF, Palatini J, Huebner K and Croce CM: Breast cancer signatures for invasiveness and prognosis defined by deep sequencing of microRNA. Proc Natl Acad Sci USA. 109:3024–3029. 2012. View Article : Google Scholar : PubMed/NCBI
40	Garzon R, Calin GA and Croce CM: MicroRNAs in cancer. Ann Rev Med. 60:167–179. 2009. View Article : Google Scholar : PubMed/NCBI
41	Klinge CM: Non-coding RNAs in breast cancer: Intracellular and intercellular communication. Noncoding RNA. 4:402018.
42	Kanasty R, Dorkin JR, Vegas A and Anderson D: Delivery materials for siRNA therapeutics. Nat Materials. 12:967–977. 2013. View Article : Google Scholar : PubMed/NCBI
43	Majumder S and Jacob ST: Emerging role of microRNAs in drug-resistant breast cancer. Gene Expr. 15:141–151. 2011. View Article : Google Scholar : PubMed/NCBI
44	Papadaki C, Stratigos M, Markakis G, Spiliotaki M, Mastrostamatis G, Nikolaou C, Mavroudis D and Agelaki S: Circulating microRNAs in the early prediction of disease recurrence in primary breast cancer. Breast Cancer Res. 20:722018. View Article : Google Scholar : PubMed/NCBI
45	Quan Y, Huang X and Quan X: Expression of miRNA-206 and miRNA-145 in breast cancer and correlation with prognosis. Oncol Lett. 16:6638–6642. 2018.PubMed/NCBI
46	Wang H, Peng R, Wang J, Qin Z and Xue L: Circulating microRNAs as potential cancer biomarkers: The advantage and disadvantage. Clinical Epigenetics. 10:592018. View Article : Google Scholar : PubMed/NCBI
47	Abdelrahim M, Safe S, Baker C and Abudayyeh A: RNAi and cancer: Implications and applications. J RNAi Gene Silencing. 2:136–145. 2006.PubMed/NCBI
48	Ewert KK, Zidovska A, Ahmad A, Bouxsein NF, Evans HM, McAllister CS, Samuel CE and Safinya CR: Cationic liposome-nucleic acid complexes for gene delivery and silencing: Pathways and mechanisms for plasmid DNA and siRNA. Top Curr Chem. 296:191–226. 2010. View Article : Google Scholar : PubMed/NCBI
49	Lin Q, Chen J, Zhang Z and Zheng G: Lipid-based nanoparticles in the systemic delivery of siRNA. Nanomedicine. 9:105–120. 2014. View Article : Google Scholar : PubMed/NCBI
50	van Zandwijk N, Pavlakis N, Kao SC, Linton A, Boyer MJ, Clarke S, Huynh Y, Chrzanowska A, Fulham MJ, Bailey DL, et al: Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: A first-in-man, phase 1, open-label, dose-escalation study. Lancet Oncol. 18:1386–1396. 2017. View Article : Google Scholar : PubMed/NCBI
51	Hong DS, Kang YK, Borad M, Sachdev J, Ejadi S, Lim HY, Brenner AJ, Park K, Lee JL, Kim TY, et al: Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours. Br J Cancer. 122:1630–1637. 2020. View Article : Google Scholar : PubMed/NCBI
52	Anselmo AC and Mitragotri S: Nanoparticles in the clinic: An update. Bioeng Transl Med. 4:e101432019. View Article : Google Scholar : PubMed/NCBI
53	Qattan A: Gene Silencing Agents in Breast Cancer. Modulating Gene Expression-Abridging the RNAi and CRISPR-Cas9 Technologies. Singh A W..Khan M: Intech Open; 2019, View Article : Google Scholar
54	Stratton MR, Campbell PJ and Futreal PA: The cancer genome. Nature. 458:719–724. 2009. View Article : Google Scholar : PubMed/NCBI
55	Pedroso de Lima MC, Simões S, Pires P, Faneca H and Düzgüneş N: Cationic lipid-DNA complexes in gene delivery: From biophysics to biological applications. Adv Drug Deliv Rev. 47:277–294. 2001. View Article : Google Scholar : PubMed/NCBI
56	Meraz IM, Savage DJ, Segura-Ibarra V, Li J, Rhudy J, Gu J and Serda RE: Adjuvant cationic liposomes presenting MPL and IL-12 induce cell death, suppress tumor growth, and alter the cellular phenotype of tumors in a murine model of breast cancer. Mol Pharm. 11:3484–3491. 2014. View Article : Google Scholar : PubMed/NCBI
57	Yu S, Bi X, Yang L, Wu S, Yu Y, Jiang B, Zhang A, Lan K and Duan S: Co-delivery of paclitaxel and PLK1-targeted siRNA using aptamer-functionalized cationic liposome for synergistic anti-breast cancer effects in vivo. J Biomed Nanotechnol. 15:1135–1148. 2019. View Article : Google Scholar : PubMed/NCBI
58	Wang W, Shao A, Zhang N, Fang J, Ruan JJ and Ruan BH: Cationic Polymethacrylate-modified liposomes significantly enhanced doxorubicin delivery and antitumor activity. Sci Rep. 7:430362017. View Article : Google Scholar : PubMed/NCBI
59	Sun Y, Zhao Y, Zhao X, Lee RJ, Teng L and Zhou C: Enhancing the therapeutic delivery of oligonucleotides by chemical modification and nanoparticle encapsulation. Molecules. 22:17242017. View Article : Google Scholar
60	Angelini G, Pisani M, Mobbili G, Marini M and Gasbarri C: Neutral liposomes containing crown ether-lipids as potential DNA vectors. Biochim Biophys Acta. 1828:2506–2512. 2013. View Article : Google Scholar : PubMed/NCBI
61	Yan Y, Li XQ, Duan JL, Bao CJ, Cui YN, Su ZB, Xu JR, Luo Q, Chen M, Xie Y and Lu WL: Nanosized functional miRNA liposomes and application in the treatment of TNBC by silencing Slug gene. Int J Nanomedicine. 14:3645–3667. 2019. View Article : Google Scholar : PubMed/NCBI
62	Lu YC, Ou-Yang FU, Hsieh CM, Chang KJ, Chen DR, Tu CW, Wang HC and Hou MF: Pegylated liposomal doxorubicin as adjuvant therapy for stage I–III operable breast cancer. In Vivo. 30:159–163. 2016.PubMed/NCBI
63	Xu D, Tian W and Shen H: Curcumin prevents induced drug resistance: A novel function? Chin J Cancer Res. 23:218–223. 2011. View Article : Google Scholar : PubMed/NCBI
64	Tang X, Bi H, Feng J and Cao J: Effect of curcumin on multidrug resistance in resistant human gastric carcinoma cell line SGC7901/VCR. Acta Pharmacologica Sinica. 26:1009–1016. 2005. View Article : Google Scholar : PubMed/NCBI
65	Thorn CF, Oshiro C, Marsh S, Hernandez-Boussard T, McLeod H, Klein TE and Altman RB: Doxorubicin pathways: Pharmacodynamics and adverse effects. Pharmacogenet Genomics. 21:440–446. 2011. View Article : Google Scholar : PubMed/NCBI
66	Zhou S, Li J, Xu H, Zhang S, Chen X, Chen W, Yang S, Zhong S, Zhao J and Tang J: Liposomal curcumin alters chemosensitivity of breast cancer cells to Adriamycin via regulating microRNA expression. Gene. 622:1–12. 2017. View Article : Google Scholar : PubMed/NCBI
67	Golkar N, Samani SM and Tamaddon AM: Data on cell growth inhibition induced by anti-VEGF siRNA delivered by Stealth liposomes incorporating G2 PAMAM-cholesterol versus Metafectene^® as a function of exposure time and siRNA concentration. Data Brief. 8:1018–1023. 2016. View Article : Google Scholar : PubMed/NCBI
68	Chen J, Sun X, Shao R, Xu Y, Gao J and Liang W: VEGF siRNA delivered by polycation liposome-encapsulated calcium phosphate nanoparticles for tumor angiogenesis inhibition in breast cancer. Int J Nanomedicine. 12:6075–6088. 2017. View Article : Google Scholar : PubMed/NCBI
69	Leung AK, Tam YY and Cullis PR: Lipid Nanoparticles for short interfering RNA delivery. Adv Genet. 88:71–110. 2014. View Article : Google Scholar : PubMed/NCBI
70	Fernandez-Piñeiro I, Badiola I and Sanchez A: Nanocarriers for microRNA delivery in cancer medicine. Biotechnol Adv. 35:350–360. 2017. View Article : Google Scholar : PubMed/NCBI
71	Pandey H, Rani R and Agarwal V: Liposome and their applications in cancer therapy. Brazilian Arch Biol Technol. 592016.http://dx.doi.org/10.1590/1678-4324-2016150477.
72	Liu HM, Zhang YF, Xie YD, Cai YF, Li BY, Li W, Zeng LY, Li YL and Yu RT: Hypoxia-responsive ionizable liposome delivery siRNA for glioma therapy. Int J Nanomedicine. 12:1065–1083. 2017. View Article : Google Scholar : PubMed/NCBI
73	Modi S, Xiang TX and Anderson BD: Enhanced active liposomal loading of a poorly soluble ionizable drug using supersaturated drug solutions. J Control Release. 162:330–339. 2012. View Article : Google Scholar : PubMed/NCBI
74	Fenske DB, Chonn A and Cullis PR: Liposomal nanomedicines: An emerging field. Toxicol Pathol. 36:21–29. 2008. View Article : Google Scholar : PubMed/NCBI
75	Johnston MJ, Semple SC, Klimuk SK, Edwards K, Eisenhardt ML, Leng EC, Karlsson G, Yanko D and Cullis PR: Therapeutically optimized rates of drug release can be achieved by varying the drug-to-lipid ratio in liposomal vincristine formulations. Biochim Biophys Acta. 1758:55–64. 2006. View Article : Google Scholar : PubMed/NCBI
76	Lujan H, Griffin WC, Taube JH and Sayes CM: Synthesis and characterization of nanometer-sized liposomes for encapsulation and microRNA transfer to breast cancer cells. Int J Nanomedicine. 14:5159–5173. 2019. View Article : Google Scholar : PubMed/NCBI
77	de Antonellis P, Liguori L, Falanga A, Carotenuto M, Ferrucci V, Andolfo I, Marinaro F, Scognamiglio I, Virgilio A, De Rosa G, et al: MicroRNA 199b-5p delivery through stable nucleic acid lipid particles (SNALPs) in tumorigenic cell lines. Naunyn Schmiedebergs Arch Pharmacol. 386:287–302. 2013. View Article : Google Scholar : PubMed/NCBI
78	Samanta S, Rajasingh S, Drosos N, Zhou Z, Dawn B and Rajasingh J: Exosomes: New molecular targets of diseases. Acta pharmacologica Sinica. 39:501–513. 2018. View Article : Google Scholar : PubMed/NCBI
79	Bhome R, Del Vecchio F, Lee GH, Bullock MD, Primrose JN, Sayan AE and Mirnezami AH: Exosomal microRNAs (exomiRs): Small molecules with a big role in cancer. Cancer Lett. 420:228–235. 2018. View Article : Google Scholar : PubMed/NCBI
80	Zhang J, Li S, Li L, Li M, Guo C, Yao J and Mi S: Exosome and exosomal microRNA: Trafficking, sorting, and function. Genomics Proteomics Bioinformatics. 13:17–24. 2015. View Article : Google Scholar : PubMed/NCBI
81	Xin Y, Wang X, Meng K, Ni C, Lv Z and Guan D: Identification of exosomal miR-455-5p and miR-1255a as therapeutic targets for breast cancer. Biosci Rep. 40:BSR201903032020. View Article : Google Scholar : PubMed/NCBI
82	Harris DA, Patel SH, Gucek M, Hendrix A, Westbroek W and Taraska JW: Exosomes released from breast cancer carcinomas stimulate cell movement. PLoS One. 10:e01174952015. View Article : Google Scholar : PubMed/NCBI
83	Lin R, Wang S and Zhao RC: Exosomes from human adipose-derived mesenchymal stem cells promote migration through Wnt signaling pathway in a breast cancer cell model. Mol Cell Biochem. 383:13–20. 2013. View Article : Google Scholar : PubMed/NCBI
84	Wu CY, Du SL, Zhang J, Liang AL and Liu YJ: Exosomes and breast cancer: A comprehensive review of novel therapeutic strategies from diagnosis to treatment. Cancer Gene Ther. 24:6–12. 2017. View Article : Google Scholar : PubMed/NCBI
85	Taylor DD and Gercel-Taylor C: MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol. 110:13–21. 2008. View Article : Google Scholar : PubMed/NCBI
86	Silva J, Garcia V, Zaballos A, Provencio M, Lombardía L, Almonacid L, García JM, Domínguez G, Peña C, Diaz R, et al: Vesicle-related microRNAs in plasma of nonsmall cell lung cancer patients and correlation with survival. Eur Respir J. 37:617–623. 2011. View Article : Google Scholar : PubMed/NCBI
87	Rabinowits G, Gerçel-Taylor C, Day JM, Taylor DD and Kloecker GH: Exosomal MicroRNA: A diagnostic marker for lung cancer. Clinical Lung Cancer. 10:42–46. 2009. View Article : Google Scholar : PubMed/NCBI
88	Wu H, Wang Q, Zhong H, Li L, Zhang Q, Huang Q and Yu Z: Differentially expressed microRNAs in exosomes of patients with breast cancer revealed by next-generation sequencing. Oncol Rep. 43:240–250. 2019.PubMed/NCBI
89	Allen TM, Hansen C, Martin F, Redemann C and Yau-Young A: Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. Biochim Biophys Acta. 1066:29–36. 1991. View Article : Google Scholar : PubMed/NCBI
90	Klibanov AL, Maruyama K, Torchilin VP and Huang L: Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett. 268:235–237. 1990. View Article : Google Scholar : PubMed/NCBI
91	Senior J, Delgado C, Fisher D, Tilcock C and Gregoriadis G: Influence of surface hydrophilicity of liposomes on their interaction with plasma protein and clearance from the circulation: Studies with poly(ethylene glycol)-coated vesicles. Biochim Biophys Acta. 1062:77–82. 1991. View Article : Google Scholar : PubMed/NCBI
92	Immordino ML, Dosio F and Cattel L: Stealth liposomes: Review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomedicine. 1:297–315. 2006.PubMed/NCBI
93	Caliceti P: Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates. Adv Drug Delivery Rev. 55:1261–1277. 2003. View Article : Google Scholar
94	Barenholz Y: Doxil^®−The first FDA-approved Nano-drug: Lessons learned. J Control Release. 160:117–134. 2012. View Article : Google Scholar : PubMed/NCBI
95	Vakhshiteh F, Khabazian E, Atyabi F, Ostad SN, Madjd Z and Dinarvand R: Peptide-conjugated liposomes for targeted miR-34a delivery to suppress breast cancer and cancer stem-like population. J Drug Deliv Sci Technol. 57:1016872020. View Article : Google Scholar
96	Amstad E, Kohlbrecher J, Müller E, Schweizer T, Textor M and Reimhult E: Triggered release from liposomes through magnetic actuation of iron oxide nanoparticle containing membranes. Nano Lett. 11:1664–1670. 2011. View Article : Google Scholar : PubMed/NCBI
97	Nahire R, Hossain R, Patel R, Paul S, Meghnani V, Ambre AH, Gange KN, Katti KS, Leclerc E, Srivastava DK, et al: pH-Triggered echogenicity and contents release from liposomes. Mol Pharm. 11:4059–4068. 2014. View Article : Google Scholar : PubMed/NCBI
98	Khan DR, Webb MN, Cadotte TH and Gavette MN: Use of targeted liposome-based chemotherapeutics to treat breast cancer. Breast Cancer (Auckl). 9 (Suppl 2):S1–S5. 2015.
99	Ta T and Porter TM: Thermosensitive liposomes for localized delivery and triggered release of chemotherapy. J Control Release. 169:112–125. 2013. View Article : Google Scholar : PubMed/NCBI
100	Elegbede AI, Banerjee J, Hanson AJ, Tobwala S, Ganguli B, Wang R, Lu X, Srivastava DK and Mallik S: Mechanistic studies of the triggered release of liposomal contents by matrix metalloproteinase-9. J Am Chem Soc. 130:10633–10642. 2008. View Article : Google Scholar : PubMed/NCBI
101	Brown S and Khan DR: The treatment of breast cancer using liposome technology. J Drug Deliv. 2012:2129652012. View Article : Google Scholar : PubMed/NCBI
102	Sneider A, Jadia R, Piel B, VanDyke D, Tsiros C and Rai P: Engineering remotely triggered liposomes to target triple negative breast cancer. Oncomedicine. 2:1–13. 2017. View Article : Google Scholar : PubMed/NCBI
103	Yang G, Liu Z, Li Y, Hou Y, Fei X, Su C, Wang S, Zhuang Z and Guo Z: Facile synthesis of black phosphorus-Au nanocomposites for enhanced photothermal cancer therapy and surface-enhanced Raman scattering analysis. Biomater Sci. 5:2048–2055. 2017. View Article : Google Scholar : PubMed/NCBI
104	Qiu M, Ren WX, Jeong T, Won M, Park GY, Sang DK, Liu LP, Zhang H and Kim JS: Omnipotent phosphorene: A next-generation, two-dimensional nanoplatform for multidisciplinary biomedical applications. Chem Soc Rev. 47:5588–5601. 2018. View Article : Google Scholar : PubMed/NCBI
105	Sun S, Xu Y, Fu P, Chen M, Sun S, Zhao R, Wang J, Liang X and Wang S: Ultrasound-targeted photodynamic and gene dual therapy for effectively inhibiting triple negative breast cancer by cationic porphyrin lipid microbubbles loaded with HIF1α-siRNA. Nanoscale. 10:19945–19956. 2018. View Article : Google Scholar : PubMed/NCBI
106	Tang J, Li B, Howard CB, Mahler SM, Thurecht KJ, Wu Y, Huang L and Xu ZP: Multifunctional lipid-coated calcium phosphate nanoplatforms for complete inhibition of large triple negative breast cancer via targeted combined therapy. Biomaterials. 216:1192322019. View Article : Google Scholar : PubMed/NCBI
107	Ghasemiyeh P and Mohammadi-Samani S: Solid lipid nanoparticles and nanostructured lipid carriers as novel drug delivery systems: Applications, advantages and disadvantages. Res Pharma Sci. 13:288–303. 2018. View Article : Google Scholar